Dr. Lal Path Labs Ltd. Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Excellent return on equity (ROE 22.3%)
- Efficient capital deployment (ROCE 28%)
- Virtually debt-free
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
LALPATHLAB · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 54.60% | 54.60% | 54.60% | 53.92% | 53.91% | 53.91% |
| FII | 25.36% | 26.15% | 25.43% | 26.82% | 26.82% | 23.90% |
| DII | 9.27% | 9.40% | 12.42% | 12.60% | 12.88% | 15.79% |
| Public | 10.12% | 9.24% | 6.95% | 6.02% | 5.82% | 5.84% |
| Govt | 0.29% | 0.29% | 0.29% | 0.29% | 0.29% | 0.29% |
| Others | 0.37% | 0.32% | 0.30% | 0.33% | 0.28% | 0.27% |
Corporate Events
To consider 2nd interim dividend for FY 26-27, if any
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Interim Dividend - Rs 5 Per Share
To consider and approve the financial results for the period ending Jun 30, 2026 and other business mattersPlease note that this Board Meeting pertains to the Financial Year 2026 2027. However, while submitting this announcement, the Financial Year is bei
To consider Interim dividend for FY 2026-27, if any,
Dividend - Rs 4 Per Share
Record: 25 Jun 2026
To consider and recommend Final Dividend for FY 2025-26, if any
To consider and approve the financial results for the period ended March 31, 2026 and other business matters
Interim Dividend - Rs 3.50 Per Share
Bonus 1:1
Latest News
All news16 stocks including Adani Enterprises, Polycab in focus
*16 stocks including Adani Enterprises, Polycab in focus* amid increased trading activity and F&O interest. Names like **BEL**, **RailTel**, and **Dr Lal Path** are seeing elevated volumes. **ICICI Life Insurance** and **Aegis Logistics** also feature in the buzz list. Market analysts suggest caution due to volatility in these counters. 📊 *STOCKS:* ADANIENT, POLYCAB, ICICIPRULI, AEGISLOG, RAILTEL, LALPATHLAB, BEL | 🏢 *SECTOR:* Trading | #MEDIUMIMPACT #Trading
Dr. Lal Path Labs shares stable after general updates
*Dr. Lal Path游戏副本 Labs shares showed no significant movement following a routine corporate filing.* The company informed the exchange about general updates, though no specific financial or operational details were disclosed. Such filings typically do not impact trading sentiment. Investors await clearer signals from upcoming earnings or management commentary. 📊 *STOCKS:* $LALPATHLAB | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #CorporateUpdate
Dr. Lal Path Labs publishes statutory notice in newspaper
*Dr. Lal Path Labs publishes statutory notice in newspaper* — The company has filed a copy of its newspaper publication with the exchange, as part of regulatory compliance. This is a routine disclosure with no immediate financial implications. Such filings are standard for listed entities to meet public notice requirements. 📊 *STOCKS:* $LALPATHLAB | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #Statutory
Dr. Lal Path Labs publishes statutory notice
*Dr. Lal Path Labs publishes statutory notice* Dr. Lal Path Labs Ltd. has submitted a copy of its newspaper publication to the exchange as part of regulatory compliance. The filing does not disclose any financial or operational update. Such disclosures are routine and typically informational in nature. 📊 *STOCKS:* LALPATHLAB | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #corporatefiling
Dr. Lal Path Labs submits sustainability report for FY 2025-26
*Dr. Lal Path Labs submits sustainability report for FY 2025-26.* The company has filed its Business Responsibility and Sustainability Report with the NSE. This is a routine regulatory disclosure and does not contain financial or operational updates. Such filings are part of ongoing compliance requirements. 📊 *STOCKS:* DRLALPATH | 🏢 *SECTOR:* Corporate | #LOWIMPACT #Sustainability
Dr. Lal Path Labs to hold AGM on July 25, 2026
*Dr. Lal Path Labs to hold AGM on July 25, 2026.* The company has informed the exchange about the notice of its Annual General Meeting. This is a routine corporate exercise with no immediate financial impact. Investors may expect updates on business performance and governance. 📊 *STOCKS:* LALPATHLAB | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #CorporateEvent
Dr. Lal Path Labs publishes newspaper notice
*Dr. Lal Path Labs publishes newspaper notice.* The company has submitted a copy of its newspaper publication to the exchange as part of regulatory compliance. This is a routine disclosure with no immediate financial implications. **No monetary figure** or strategic update was disclosed. 📊 *STOCKS:* LALPATHLAB | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #corporate
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹660 Cr 9.7% | ₹731 Cr 9.1% | ₹670 Cr 11.1% | ₹603 Cr 1.0% | ₹597 Cr 9.5% | ₹660 Cr 9.6% | ₹602 Cr 10.5% | ₹545 Cr |
| Op. Profit | ₹179 Cr 20.1% | ₹224 Cr 16.7% | ₹192 Cr 13.6% | ₹169 Cr 9.7% | ₹154 Cr 23.8% | ₹202 Cr 18.8% | ₹170 Cr 17.2% | ₹145 Cr |
| OPM | 27.0% 12.9% | 31.0% 6.9% | 29.0% 3.6% | 28.0% 7.7% | 26.0% 16.1% | 31.0% 10.7% | 28.0% 3.7% | 27.0% |
| Net Profit | ₹91 Cr 40.1% | ₹152 Cr 13.4% | ₹134 Cr 14.1% | ₹156 Cr 59.2% | ₹98 Cr 25.2% | ₹131 Cr 21.3% | ₹108 Cr 25.6% | ₹86 Cr |
| EPS (₹) | 5.4 39.9% | 8.99 13.8% | 7.9 14.7% | 9.26 60.2% | 5.78 25.2% | 7.73 21.4% | 6.37 25.9% | 5.06 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2.8K Cr 12.3% | ₹2.5K Cr 10.5% | ₹2.2K Cr 10.4% | ₹2.0K Cr 3.4% | ₹2.1K Cr 32.0% | ₹1.6K Cr 18.9% | ₹1.3K Cr 10.6% | ₹1.2K Cr 13.8% | ₹1.1K Cr 15.9% | ₹912 Cr |
| Expenses | ₹2.0K Cr 12.2% | ₹1.8K Cr 9.1% | ₹1.6K Cr 5.9% | ₹1.5K Cr 0.1% | ₹1.5K Cr 33.3% | ₹1.1K Cr 16.0% | ₹987 Cr 8.5% | ₹910 Cr 14.8% | ₹793 Cr 17.5% | ₹675 Cr |
| Op. Profit | ₹783 Cr 12.2% | ₹698 Cr 14.6% | ₹609 Cr 24.3% | ₹490 Cr 12.7% | ₹561 Cr 28.7% | ₹436 Cr 26.7% | ₹344 Cr 17.0% | ₹294 Cr 11.4% | ₹264 Cr 10.9% | ₹238 Cr |
| OPM | 28.0% 0.0% | 28.0% 3.7% | 27.0% 12.5% | 24.0% 11.1% | 27.0% 3.6% | 28.0% 7.7% | 26.0% 8.3% | 24.0% 4.0% | 25.0% 3.8% | 26.0% |
| Other Income | ₹70 Cr 23.1% | ₹91 Cr 31.9% | ₹69 Cr 64.3% | ₹42 Cr 19.2% | ₹52 Cr 2.0% | ₹51 Cr 7.3% | ₹55 Cr 19.6% | ₹46 Cr 48.4% | ₹31 Cr 14.8% | ₹27 Cr |
| Interest | ₹23 Cr 4.5% | ₹22 Cr 24.1% | ₹29 Cr 23.7% | ₹38 Cr 26.7% | ₹30 Cr 87.5% | ₹16 Cr 6.7% | ₹15 Cr 1400.0% | ₹1 Cr 0.0% | ₹1 Cr 0.0% | ₹1 Cr |
| Depreciation | ₹162 Cr 14.1% | ₹142 Cr 1.4% | ₹144 Cr 4.0% | ₹150 Cr 38.9% | ₹108 Cr 40.3% | ₹77 Cr 5.5% | ₹73 Cr 92.1% | ₹38 Cr 15.2% | ₹33 Cr 17.9% | ₹28 Cr |
| PBT | ₹669 Cr 7.0% | ₹625 Cr 23.8% | ₹505 Cr 46.8% | ₹344 Cr 27.6% | ₹475 Cr 20.6% | ₹394 Cr 27.1% | ₹310 Cr 3.0% | ₹301 Cr 15.3% | ₹261 Cr 10.1% | ₹237 Cr |
| Tax % | 24.0% 14.3% | 21.0% 25.0% | 28.0% 6.7% | 30.0% 15.4% | 26.0% 4.0% | 25.0% 7.4% | 27.0% 18.2% | 33.0% 2.9% | 34.0% 0.0% | 34.0% |
| Net Profit | ₹510 Cr 3.7% | ₹492 Cr 35.9% | ₹362 Cr 50.2% | ₹241 Cr 31.1% | ₹350 Cr 18.2% | ₹296 Cr 29.8% | ₹228 Cr 14.0% | ₹200 Cr 16.3% | ₹172 Cr 10.3% | ₹156 Cr |
| EPS (₹) | 30.13 3.4% | 29.14 36.0% | 21.42 49.5% | 14.33 30.7% | 20.69 18.3% | 17.49 29.1% | 13.55 13.4% | 11.95 16.7% | 10.24 10.0% | 9.31 |
| Div Payout | 68.0% 65.9% | 41.0% | 0.0% 100.0% | 42.0% 44.8% | 29.0% 49.1% | 57.0% 29.5% | 44.0% 76.0% | 25.0% 13.6% | 22.0% 37.5% | 16.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹84 Cr 0.0% | ₹84 Cr 1.2% | ₹83 Cr 0.0% | ₹83 Cr 0.0% | ₹83 Cr 0.0% | ₹83 Cr 0.0% | ₹83 Cr 0.0% | ₹83 Cr 0.0% | ₹83 Cr 0.0% | ₹83 Cr |
| Reserves | ₹2.3K Cr 10.3% | ₹2.1K Cr 18.3% | ₹1.8K Cr 11.6% | ₹1.6K Cr 11.6% | ₹1.4K Cr 22.0% | ₹1.2K Cr 22.4% | ₹949 Cr 10.1% | ₹862 Cr 22.3% | ₹705 Cr 37.7% | ₹512 Cr |
| Borrowings | ₹156 Cr 0.6% | ₹157 Cr 36.4% | ₹247 Cr 41.2% | ₹420 Cr 21.2% | ₹533 Cr 255.3% | ₹150 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other Liabilities | ₹415 Cr 8.4% | ₹383 Cr 7.3% | ₹357 Cr 20.2% | ₹297 Cr 3.9% | ₹309 Cr 16.6% | ₹265 Cr 22.3% | ₹341 Cr 135.2% | ₹145 Cr 13.3% | ₹128 Cr 34.7% | ₹95 Cr |
| Total Liabilities | ₹3.0K Cr 9.1% | ₹2.7K Cr 10.6% | ₹2.5K Cr 3.0% | ₹2.4K Cr 1.7% | ₹2.3K Cr 41.1% | ₹1.7K Cr 20.9% | ₹1.4K Cr 25.9% | ₹1.1K Cr 19.1% | ₹916 Cr 32.8% | ₹690 Cr |
Assets | ||||||||||
| Fixed Assets | ₹1.2K Cr 5.5% | ₹1.2K Cr 4.9% | ₹1.2K Cr 5.9% | ₹1.3K Cr 4.7% | ₹1.4K Cr 206.3% | ₹447 Cr 8.2% | ₹413 Cr 97.6% | ₹209 Cr 0.5% | ₹208 Cr 36.8% | ₹152 Cr |
| CWIP | ₹17 Cr 466.7% | ₹3 Cr 50.0% | ₹6 Cr 20.0% | ₹5 Cr 66.7% | ₹15 Cr 50.0% | ₹10 Cr 9.1% | ₹11 Cr 266.7% | ₹3 Cr 70.0% | ₹10 Cr 44.4% | ₹18 Cr |
| Investments | ₹486 Cr 48.6% | ₹327 Cr 186.8% | ₹114 Cr 24.0% | ₹150 Cr 130.8% | ₹65 Cr 10.2% | ₹59 Cr 64.0% | ₹164 Cr 11.4% | ₹185 Cr 27.6% | ₹145 Cr 36.8% | ₹106 Cr |
| Other Assets | ₹1.2K Cr 0.8% | ₹1.2K Cr 9.8% | ₹1.1K Cr 19.9% | ₹923 Cr 3.4% | ₹893 Cr 21.9% | ₹1.1K Cr 45.5% | ₹786 Cr 13.3% | ₹694 Cr 25.3% | ₹554 Cr 33.8% | ₹414 Cr |
| Total Assets | ₹3.0K Cr 9.1% | ₹2.7K Cr 10.6% | ₹2.5K Cr 3.0% | ₹2.4K Cr 1.7% | ₹2.3K Cr 41.1% | ₹1.7K Cr 20.9% | ₹1.4K Cr 25.9% | ₹1.1K Cr 19.1% | ₹916 Cr 32.8% | ₹690 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹569 Cr 6.4% | ₹535 Cr 17.3% | ₹456 Cr 2.0% | ₹447 Cr 12.3% | ₹398 Cr 40.1% | ₹284 Cr 29.7% | ₹219 Cr 11.2% | ₹197 Cr 15.2% | ₹171 Cr 7.5% | ₹159 Cr |
| Investing CF | ₹-303 Cr 1162.5% | ₹-24 Cr 91.6% | ₹-287 Cr 36.1% | ₹-449 Cr 111.8% | ₹-212 Cr 715.4% | ₹-26 Cr 74.0% | ₹-100 Cr 41.9% | ₹-172 Cr 25.5% | ₹-137 Cr 16.0% | ₹-163 Cr |
| Financing CF | ₹-334 Cr 19.3% | ₹-414 Cr 46.3% | ₹-283 Cr 308.1% | ₹136 Cr 197.8% | ₹-139 Cr 26.8% | ₹-190 Cr 245.5% | ₹-55 Cr 523.1% | ₹13 Cr 140.6% | ₹-32 Cr | ₹0 Cr |
| Net Cash Flow | ₹-68 Cr 170.1% | ₹97 Cr 185.1% | ₹-114 Cr 185.1% | ₹134 Cr 179.2% | ₹48 Cr 28.4% | ₹67 Cr 4.7% | ₹64 Cr 73.0% | ₹37 Cr 1750.0% | ₹2 Cr 140.0% | ₹-5 Cr |
| Free Cash Flow | ₹516 Cr 7.7% | ₹479 Cr 16.3% | ₹412 Cr 1571.4% | ₹-28 Cr 108.3% | ₹339 Cr 65.4% | ₹205 Cr 15.8% | ₹177 Cr 41.6% | ₹125 Cr 4.2% | ₹120 Cr 4.3% | ₹115 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 13d 0.0% | 13d 0.0% | 13d 13.3% | 15d 0.0% | 15d 7.1% | 14d 12.5% | 16d 14.3% | 14d 17.6% | 17d 0.0% | 17d |
| Inventory Days | 27d 10.0% | 30d 7.1% | 28d 26.3% | 38d 2.6% | 39d 44.3% | 70d 75.0% | 40d 9.1% | 44d 33.3% | 33d 6.5% | 31d |
| Days Payable | 127d 15.9% | 151d 18.9% | 127d 18.7% | 107d 18.9% | 132d 8.3% | 144d 29.7% | 111d 4.7% | 106d 9.3% | 97d 9.0% | 89d |
| Cash Conv. Cycle | -86d 20.4% | -108d 24.1% | -87d 61.1% | -54d 30.8% | -78d 30.0% | -60d 9.1% | -55d 17.0% | -47d 0.0% | -47d 11.9% | -42d |
| Working Capital Days | -30d 34.8% | -46d 17.9% | -56d 3.7% | -54d 107.7% | -26d 36.8% | -19d | 0d 100.0% | 17d 10.5% | 19d 29.6% | 27d |
| ROCE | 29.0% 16.0% | 25.0% 38.9% | 18.0% 37.9% | 29.0% 12.1% | 33.0% 3.1% | 32.0% 8.6% | 35.0% 7.9% | 38.0% 11.6% | 43.0% 8.5% | 47.0% |
Source: Screener.in · Lower days = better efficiency